Clinical Trials Directory

Trials / Unknown

UnknownNCT02282683

Long-term Prednisone Use for End-stage Heart Failure

Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Hebei Medical University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Patients with advanced (ACCF/AHA stage D) heart failure and hyperuricemia have high one-year mortality. Currently, there was no evidence-based therapy such as mechanically assisted circulatory support available in China. The investigators found glucocorticoid treatment such as prednisone could improve cardiac performance, potentiate renal responsiveness to diuretics in such patients. Therefore, it could be used as bridge therapy to help ACE inhibitors or beta blocker titration. With its help, most of the patients with stage D heart failure could be titrated to higher dose of ACE inhibitors and beta blockers during hospitalization. However, the efficacy of long-term, low-dose of prednisone use in such patients with limited life expectancy remain unclear. Therefore, the investigators designed this study to observe whether putting low-dose of prednisone on the patients with stage D heart failure for long term could further improve their survival. All patients will receive prednisone treatment during hospitalization and receive maximum tolerated guideline-directed medical therapy (GDMT). After discharge from hospital, the patients will be randomized to receive long-term, low-dose prednisone treatment or standard GDMT.

Conditions

Interventions

TypeNameDescription
DRUGprednisonePrednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months

Timeline

Start date
2013-12-01
Primary completion
2017-12-01
Completion
2017-12-01
First posted
2014-11-04
Last updated
2017-01-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02282683. Inclusion in this directory is not an endorsement.